Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling ...

81% for early cancer stages and 82% for non-cancerous polyps. Linking the top diagnostic biomarkers to nearby genes, OBD used the EpiSwitch KnowledgeBase platform to map pathways that help ...

This test has the potential ability to detect early cancers and precancerous polyps with greater accuracy." Dr Alexandre Akoulitchev, OBD's Chief Scientific Officer added: "Reliable and non ...

Oxford BioDynamics announced the publication of a multi-institutional clinical study on Wednesday, confirming the accuracy of its EpiSwitch Colorectal No-Stool Test (NST) in detecting colorectal ...